Skip to main content
Top

Breast Cancer Research and Treatment

Issue 3/2008

Content (22 Articles)

Review

Mammographic features of triple receptor-negative primary breast cancers in young premenopausal women

Wei-Tse Yang, Mark Dryden, Kristine Broglio, Michael Gilcrease, Shaheenah Dawood, Peter J. Dempsey, Vicente Valero, Gabriel Hortobagyi, Deann Atchley, Banu Arun

Preclinical Study

αB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer

Olga Ivanov, Feng Chen, Elizabeth L. Wiley, Anjeni Keswani, Leslie K. Diaz, Heidi C. Memmel, Alfred Rademaker, William J. Gradishar, Monica Morrow, Seema A. Khan, Vincent L. Cryns

Preclinical Study

NF-κB pathway inhibitors preferentially inhibit breast cancer stem-like cells

Jiangbing Zhou, Hao Zhang, Peihua Gu, Jining Bai, Joseph B. Margolick, Ying Zhang

Preclinical Study

DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients

Inko Nimmrich, Anieta M. Sieuwerts, Marion E. Meijer-van Gelder, Ina Schwope, Joan Bolt-de Vries, Nadia Harbeck, Thomas Koenig, Oliver Hartmann, Antje Kluth, Dimo Dietrich, Viktor Magdolen, Henk Portengen, Maxime P. Look, Jan G. M. Klijn, Ralf Lesche, Manfred Schmitt, Sabine Maier, John A. Foekens, John W. M. Martens

Preclinical Study

JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer

Michael Reedijk, Dushanthi Pinnaduwage, Brendan C. Dickson, Anna Marie Mulligan, Hui Zhang, Shelley B. Bull, Frances P. O’Malley, Sean E. Egan, Irene L. Andrulis

Preclinical Study

A polymorphism in the G protein β3-subunit gene is associated with bone metastasis risk in breast cancer patients

H. Clar, U. Langsenlehner, P. Krippl, W. Renner, A. Leithner, G. Gruber, G. Hofmann, B. Yazdani-Biuki, T. Langsenlehner, R. Windhager

Preclinical Study

Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptorβ in primary invasive breast carcinomas

Gaynor J. Bates, Stephen B. Fox, Cheng Han, Rosalind Launchbury, Russell D. Leek, Adrian L. Harris, Alison H. Banham

Preclinical Study

Midregion PTHrP regulates Rip1 and caspase expression in MDA-MB231 breast cancer cells

Claudio Luparello, Rosalia Sirchia, Bruna Lo Sasso

Preclinical Study

High frequency of HIF-1α overexpression in BRCA1 related breast cancer

Petra van der Groep, Alwin Bouter, Fred H. Menko, Elsken van der Wall, Paul J. van Diest

Epidemiology

A CYP19 (aromatase) polymorphism is associated with increased premenopausal breast cancer risk

Kathryn E. Talbott, Marilie D. Gammon, Muhammad G. Kibriya, Yu Chen, Susan L. Teitelbaum, Chang-Min Long, Irina Gurvich, Regina M. Santella, Habibul Ahsan

Epidemiology

Surveillance mammography and the risk of death among elderly breast cancer patients

Mario Schootman, Donna B. Jeffe, Min Lian, Rebecca Aft, William E. Gillanders

Epidemiology

MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish–Ashkenazi descent

Ronit I. Yarden, Eitan Friedman, Sally Metsuyanim, Tsviya Olender, Edna Ben-Asher, Moshe Zvi Papa

Epidemiology

BARD1 variants are not associated with breast cancer risk in Australian familial breast cancer

Kylie L. Gorringe, David Y. H. Choong, Jane E. Visvader, Geoffrey J. Lindeman, Ian G. Campbell

Preclinical study

Tumor-derived CCL5 does not contribute to breast cancer progression

Mevan M. Jayasinghe, Jacqueline M. Golden, Priyanka Nair, Cara M. O’Donnell, Michael T. Werner, Robert A. Kurt

Epidemiology

Brain metastases in breast cancer: prognostic factors and management

Sung Sook Lee, Jin-Hee Ahn, Min Kyoung Kim, Sun Jin Sym, Gyungyub Gong, Seung Do Ahn, Sung-Bae Kim, Woo Kun Kim

Epidemiology

Differences in breast cancer biological characteristics between ethnic groups in New Zealand

M. K. Weston, D. P. Moss, J. Stewart, A. G. Hill

Epidemiology

Population attributable risks for breast cancer in Swedish women by morphological type

Charlotta Granström, Jan Sundquist, Kari Hemminki

Letter to the editor

ERCC1 expression in triple negative breast carcinoma: the paradox revisited

Angelo Sidoni, Fabio Cartaginese, Mariantonietta Colozza, Stefania Gori, Lucio Crinó

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine